NR3C2 and heart failure: However, the absence of any impacts on all-cause mortality indicates that although SGLT2i are highly beneficial in managing heart failure, they need to be used complementarily to other GTKD therapies such as mineralocorticoid receptor antagonists, beta-blockers, and renin-angiotensin-aldosterone system inhibitors that have been well-documented in their potential to lower heart failure mortality [38-40].